Revised FIGO staging for carcinoma of the cervix
2009; Elsevier BV; Volume: 105; Issue: 2 Linguagem: Inglês
10.1016/j.ijgo.2009.02.009
ISSN1879-3479
AutoresSërgio Pecorelli, Lucia Zigliani, Franco Odicino,
Tópico(s)Cervical Cancer and HPV Research
ResumoInternational Journal of Gynecology & ObstetricsVolume 105, Issue 2 p. 107-108 Special communications Revised FIGO staging for carcinoma of the cervix Sergio Pecorelli, Sergio Pecorelli Department of Obstetrics and Gynecology Oncology, University of Brescia, Brescia, Italy Chairman, FIGO Committee on Gynocologic Oncology; and Editor, FIGO Annul Report, FIGO Annual Report Editorial Office FIGO Annual Report Editorial Office, European Institute of Oncology, Milan ItalySearch for more papers by this authorLucia Zigliani, Corresponding Author Lucia Zigliani [email protected] FIGO Annual Report Editorial Office, European Institute of Oncology, Milan ItalyCorresponding author. FIGO Annual Report Editorial Office, Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. Fax: +39 0257489872.Search for more papers by this authorFranco Odicino, Franco Odicino Department of Obstetrics and Gynecology Oncology, University of Brescia, Brescia, Italy FIGO Annual Report Editorial Office, European Institute of Oncology, Milan ItalySearch for more papers by this author Sergio Pecorelli, Sergio Pecorelli Department of Obstetrics and Gynecology Oncology, University of Brescia, Brescia, Italy Chairman, FIGO Committee on Gynocologic Oncology; and Editor, FIGO Annul Report, FIGO Annual Report Editorial Office FIGO Annual Report Editorial Office, European Institute of Oncology, Milan ItalySearch for more papers by this authorLucia Zigliani, Corresponding Author Lucia Zigliani [email protected] FIGO Annual Report Editorial Office, European Institute of Oncology, Milan ItalyCorresponding author. FIGO Annual Report Editorial Office, Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. Fax: +39 0257489872.Search for more papers by this authorFranco Odicino, Franco Odicino Department of Obstetrics and Gynecology Oncology, University of Brescia, Brescia, Italy FIGO Annual Report Editorial Office, European Institute of Oncology, Milan ItalySearch for more papers by this author First published: 01 April 2009 https://doi.org/10.1016/j.ijgo.2009.02.009Citations: 509Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References [1]de Oliveira C.F., Mota F. Cervical Cancer – pre-therapeutic investigations and clinical staging versus surgical staging. CME J Gynecol Oncol. 6: 2001; 246–256 Google Scholar [2]Tropé C., Kristensen G., Onsrud M., Bosze P. Controversies in cervical cancer staging. CME J Gynecol Oncol. 6: 2001; 240–245 Google Scholar [3]Amendola M.A., Hricak H., Mitchell D.G., Snyder B., Chi D.S., Long H.J. III, et al. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol. 23, (30): 2005; 7454–7459 10.1200/JCO.2004.00.5397 PubMedWeb of Science®Google Scholar [4]Hricak H. First open trial of the American College of Radiology Imaging Network: proper imaging approach for invasive cervical cancer. Radiology. 225, (3): 2002; 634–635 10.1148/radiol.2253020725 PubMedWeb of Science®Google Scholar [5]Mitchell D.G., Snyder B., Coakley F., Reinhold C., Thomas G., Amendola M., et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 24, (36): 2006; 5687–5694 10.1200/JCO.2006.07.4799 PubMedWeb of Science®Google Scholar [6]Hricak H., Gatsonis C., Coakley F.V., Snyder B., Reinhold C., Schwartz L.H., et al. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performace and interobserver variability. Radiology. 245, (2): 2007; 491–498 10.1148/radiol.2452061983 PubMedWeb of Science®Google Scholar [7]Lagasse L.D., Creasman W.T., Shingleton H.M., Ford J.H., Blessing J.A. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol. 9, (1): 1980; 90–98 10.1016/0090-8258(80)90013-X PubMedWeb of Science®Google Scholar [8] P. Boyle, C. la Vecchia, A. Walker Annual Report on the Results of Treatment in Gynecological Cancer. Twenty-fourth volume. J Epidemiol Biostat. vol. 6, (1): 2001; 1–184 Google Scholar [9] S. Pecorelli 25th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet. vol. 83(Suppl 1): 2003; S1–230 Google Scholar [10] S. Pecorelli 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet. vol. 95(Suppl 1): 2006; S1–258 Web of Science®Google Scholar [11]Burghardt E., Ostör A., Fox H. The new FIGO definition of cervical cancer stage IA: a critique. Gynecol Oncol. 65, (1): 1997; 1–5 10.1006/gyno.1997.4672 PubMedWeb of Science®Google Scholar [12]Piver M.S., Chung W.S. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol. 46, (5): 1975; 507–510 CASPubMedWeb of Science®Google Scholar [13]Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Gynecol Oncol. 38, (3): 1990; 352–357 10.1016/0090-8258(90)90072-S PubMedWeb of Science®Google Scholar [14]Perez C.A., Grigsby P.W., Chao K.S., Mutch D.G., Lockett M.A. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys. 41, (2): 1998; 307–317 10.1016/S0360-3016(98)00067-4 PubMedWeb of Science®Google Scholar [15]Horn L.C., Fischer U., Raptis G., Bilek K., Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 107, (2): 2007; 310–315 10.1016/j.ygyno.2007.06.026 PubMedWeb of Science®Google Scholar [16]Cheng X., Cai S., Li Z., Tang M., Xue M., Zang R. The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. World J Surg Oncol. 18;2: 2004; 47 10.1186/1477-7819-2-47 Google Scholar [17]Graflund M., Sorbe B., Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. Int J Gynecol Cancer. 12, (3): 2002 290–298 10.1046/j.1525-1438.2002.01113.x PubMedWeb of Science®Google Scholar [18]Aoki Y., Sasaki M., Watanabe M., Sato T., Tsuneki I., Aida H., et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecol Oncol. 77, (2): 2000; 305–309 10.1006/gyno.2000.5788 PubMedWeb of Science®Google Scholar [19]Sakuragi N., Satoh C., Takeda N., Hareyama H., Takeda M., Yamamoto R., et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer. 85, (7): 1999; 1547–1554 10.1002/(SICI)1097-0142(19990401)85:7 3.0.CO;2-2 PubMedWeb of Science®Google Scholar [20]Benedetti-Panici P., Maneschi F., D'Andrea G., Cutillo G., Rabitti C., Congiu M., et al. Early cervical carcinoma: the natural history of lymph node involvement redefined on the basis of thorough parametrectomy and giant section study. Cancer. 88, (10): 2000; 2267–2274, [Erratum in: Cancer 2000;89(2):473] 10.1002/(SICI)1097-0142(20000515)88:10 3.0.CO;2-9 PubMedWeb of Science®Google Scholar [21]Narayan K., McKenzie A.F., Hicks R.J., Fisher R., Bernshaw D., Bau S. Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy. Int J Gynecol Cancer. 13, (5): 2003; 657–663 10.1046/j.1525-1438.2003.13026.x PubMedWeb of Science®Google Scholar [22]Grigsby P.W., Siegel B.A., Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 19, (17): 2001; 3745–3749 10.1200/JCO.2001.19.17.3745 CASPubMedWeb of Science®Google Scholar [23]Kawagoe T., Kashimura M., Matsuura Y., Sugihara K., Toki N., Aoki T. Clinical significance of tumor size in stage IB and II carcinoma of the uterine cervix. Int J Gynecol Cancer. 9, (5): 1999; 421–426 10.1046/j.1525-1438.1999.99059.x PubMedWeb of Science®Google Scholar [24]Togashi K., Morikawa K., Kataoka M.L., Konishi J. Cervical cancer. J Magn Reson Imaging. 8, (2): 1998; 391–397 10.1002/jmri.1880080219 PubMedWeb of Science®Google Scholar [25]Grigsby P.W. 4th International Cervical Cancer Conference: update on PET and cervical cancer. Gynecol Oncol. 99, (3 Suppl 1): 2005; S173–S175 10.1016/j.ygyno.2005.07.076 PubMedWeb of Science®Google Scholar [26]Hong J.H., Tsai C.S., Lai C.H., Chang T.C., Wang C.C., Chou H.H., et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys. 63, (2): 2005; 492–499 10.1016/j.ijrobp.2005.02.012 PubMedWeb of Science®Google Scholar Citing Literature Volume105, Issue2May 2009Pages 107-108 ReferencesRelatedInformation
Referência(s)